Oruka Therapeutics (ORKA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.55
- Estimate
- -$0.50
- Surprise
- -9.9%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Oruka Therapeutics (ORKA) reported a wider loss than forecast — diluted EPS of -$0.55 against the -$0.50 estimate (a 9.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ORKA Sell at 5.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -9.9% surprise compares with a +5.6% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: ORKA-001 and ORKA-002
- Concentration risk — Supplier: Paragon
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $92.51
- Price target
- $134.85
- Stop
- $86.03
- Upside to target
- +45.8%
- Reward-to-risk
- 3.9:1
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
ORKA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.13B
- P/E (fwd)
- -32.3
- 52-week range
- $14.67–$115.52
- Off 52-week high
- 19.9%
- RSI (14)
- 20
- Volume vs avg
- 0.73×
- Score today
- 5.4/10